Human-factors validation study for a wearable, single-use...
Submitting Author Hanaa Shahin
Oct 8, 2024 10:31 AM CDT
Pegcetacoplan is a complement component 3 inhibitor approved to treat adults with paroxysmal nocturnal hemoglobinuria, a rare disease characterized by life-threatening complement-mediated hemolysis (often leading to anemia) and thrombosis.... Read More
30 Views